156 related articles for article (PubMed ID: 23558935)
21. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
[TBL] [Abstract][Full Text] [Related]
22. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
Le Roy B; Tixier L; Pereira B; Sauvanet P; Buc E; Pétorin C; Déchelotte P; Pezet D; Balayssac D
PLoS One; 2016; 11(2):e0148739. PubMed ID: 26859833
[TBL] [Abstract][Full Text] [Related]
23. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Iwasa S; Nagashima K; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Yasui H; Kato K; Okita NT; Shimada Y; Yamada Y
Cancer Chemother Pharmacol; 2015 Sep; 76(3):605-14. PubMed ID: 26220845
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
[TBL] [Abstract][Full Text] [Related]
25. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
26. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.
Bir A; Tan W; Wilding GE; Lombardo J; Fakih MG
Oncology; 2007; 72(1-2):4-9. PubMed ID: 17971679
[TBL] [Abstract][Full Text] [Related]
27. FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
Nozawa H; Kitayama J; Sunami E; Saito S; Kanazawa T; Kazama S; Yazawa K; Kawai K; Mori K; Nagawa H
Oncology; 2011; 80(1-2):84-91. PubMed ID: 21677451
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
Boige V; Mendiboure J; Pignon JP; Loriot MA; Castaing M; Barrois M; Malka D; Trégouët DA; Bouché O; Le Corre D; Miran I; Mulot C; Ducreux M; Beaune P; Laurent-Puig P
J Clin Oncol; 2010 May; 28(15):2556-64. PubMed ID: 20385995
[TBL] [Abstract][Full Text] [Related]
29. FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms.
Lu W; Fu D; Kong X; Huang Z; Hwang M; Zhu Y; Chen L; Jiang K; Li X; Wu Y; Li J; Yuan Y; Ding K
Cancer Med; 2020 Feb; 9(4):1419-1429. PubMed ID: 31893575
[TBL] [Abstract][Full Text] [Related]
30. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
31. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
32. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
Seki H; Ozaki T; Shiina M
Cardiovasc Intervent Radiol; 2009 Jul; 32(4):679-86. PubMed ID: 19296157
[TBL] [Abstract][Full Text] [Related]
33. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
35. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
Vaidyanathan G; Groman A; Wilding G; Fakih MG
Oncology; 2010; 79(1-2):67-71. PubMed ID: 21071992
[TBL] [Abstract][Full Text] [Related]
36. Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
Tsutsumi S; Fujii T; Yamaguchi S; Suto T; Yajima R; Morita H; Kato T; Asao T; Kuwano H
Hepatogastroenterology; 2014 May; 61(131):633-7. PubMed ID: 26176048
[TBL] [Abstract][Full Text] [Related]
37. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience.
Cvetanovic A; Vrbic S; Filipovic S; Pejcic I; Milenkovic D; Milenkovic N; Zivkovic N
J BUON; 2013; 18(3):641-6. PubMed ID: 24065477
[TBL] [Abstract][Full Text] [Related]
39. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
[TBL] [Abstract][Full Text] [Related]
40. High- versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer.
Reynolds J; Chamberland-Tremblay A; Herrington JD; Munoz Maldonado Y; Wong L
J Oncol Pharm Pract; 2017 Apr; 23(3):173-178. PubMed ID: 26786027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
